These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 12209588)
1. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Kurokawa T; Fischer K; Bertz H; Hoegerle S; Finke J; Mackensen A Int J Cancer; 2002 Sep; 101(1):52-60. PubMed ID: 12209588 [TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611 [TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
5. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296 [TBL] [Abstract][Full Text] [Related]
6. Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermates. Georges GE; Lesnikova M; Storb R; Yunusov M; Little MT; Nash RA Biol Blood Marrow Transplant; 2003 Apr; 9(4):234-42. PubMed ID: 12720216 [TBL] [Abstract][Full Text] [Related]
7. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Kurokawa T; Oelke M; Mackensen A Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975 [TBL] [Abstract][Full Text] [Related]
8. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403 [TBL] [Abstract][Full Text] [Related]
9. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264 [TBL] [Abstract][Full Text] [Related]
10. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562 [TBL] [Abstract][Full Text] [Related]
11. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017 [TBL] [Abstract][Full Text] [Related]
12. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783 [TBL] [Abstract][Full Text] [Related]
13. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020 [TBL] [Abstract][Full Text] [Related]
14. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
15. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892 [TBL] [Abstract][Full Text] [Related]
16. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma. van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741 [TBL] [Abstract][Full Text] [Related]
17. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766 [TBL] [Abstract][Full Text] [Related]
19. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. Bishop MR; Fowler DH; Marchigiani D; Castro K; Kasten-Sportes C; Steinberg SM; Gea-Banacloche JC; Dean R; Chow CK; Carter C; Read EJ; Leitman S; Gress R J Clin Oncol; 2004 Oct; 22(19):3886-92. PubMed ID: 15314059 [TBL] [Abstract][Full Text] [Related]
20. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. Slavin S; Morecki S; Weiss L; Or R J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]